External quality assessment demonstrates that PD‐L1 22C3 and SP263 assays are systematically different

• Main Authors: Andrew Dodson (Author), Suzanne Parry (Author), Birgit Lissenberg‐Witte (Author), Alex Haragan (Author), David Allen (Author), Anthony O'Grady (Author), Emma McClean (Author), Jamie Hughes (Author), Keith Miller (Author), Erik Thunnissen (Author)
• Format: Book
• Published: Wiley, 2020-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract PD‐L1 inhibitors are part of first line treatment options for patients with advanced non‐small cell lung cancer. PD‐L1 immunohistochemistry (IHC) assays act as either a companion or a complementary diagnostic. The purpose of this study is to describe the experience of external quality assur...